Diabetic Nephropathy but not HbA1c is Predictive for Frequent Complications of Charcot Feet – Long-term follow-up of 164 Consecutive Patients with 195 Acute Charcot Feet

A. Sämann; S. Pofahl; T. Lehmann; B. Voigt; S. Victor; F. Möller; U. A. Müller; G. Wolf

doi:10.1055/s-0031-1299705

Experimental and Clinical Endocrinology & Diabetes, Inhaltsverzeichnis

Exp Clin Endocrinol Diabetes 2012; 120(06): 335-339
DOI: 10.1055/s-0031-1299705

Article

Diabetic Nephropathy but not HbA1c is Predictive for Frequent Complications of Charcot Feet – Long-term follow-up of 164 Consecutive Patients with 195 Acute Charcot Feet

A. Sämann

¹Clinic for Nephrology, Saalfeld, Germany

,

S. Pofahl

²Department of Internal Medicine III, Friedrich-Schiller-University, Jena, Germany

,

T. Lehmann

³Institute of Medical Statistics, Information Sciences and Documentation, Friedrich-Schiller-University, Jena, Germany

,

B. Voigt

⁴MediClin Klinik am Rennsteig, Tabarz, Germany

,

S. Victor

⁴MediClin Klinik am Rennsteig, Tabarz, Germany

,

F. Möller

⁴MediClin Klinik am Rennsteig, Tabarz, Germany

,

U. A. Müller

²Department of Internal Medicine III, Friedrich-Schiller-University, Jena, Germany

,

G. Wolf

²Department of Internal Medicine III, Friedrich-Schiller-University, Jena, Germany

› Institutsangaben

Abstract

Aims:

To investigate the clinical characteristics, treatment and long-term outcome of patients with acute Charcot feet (CF).

Methods:

Single-center retrospective analysis. Treatment of CF: stage-dependent immobilization/weight-off therapy, orthopaedic/adjusted shoes, foot surgery. 164 consecutive participants (type 1 vs. type 2 diabetes): 12 vs. 150, non-diabetic peripheral neuropathy: n=2, presented with 195 (17 vs. 176) CF. Mean follow-up: 4.7±2.5 (range 2.2–9.8) vs. 5.4±2.9 (range 0.8–18.8) years, vital at follow-up: 100 vs. 88%.

Results:

Baseline characteristics: age: 43.7±10.9 vs. 57.9±8.9 years (p<0.001), male gender: 66.7 vs. 77.3%, diabetes duration: 19.2±9.1 vs. 13±8.6 years (p=0.018), GHb: 8.1±2.4 vs. 7.6±1.6%, BMI: 24±5.3 vs. 33.7±6.5 kg/m² (p<0.001), Levine 1: 18.2 vs. 7.4%, Levine 2: 45.5 vs. 65.9%, Sanders 2: 58.3 vs. 68.5%, Sanders 3: 33.3 vs. 45%. Therapy: immobilization for 6±4.2 vs. 5.4±4.5 months, orthopaedic/adjusted shoes: 27.3 vs. 20.5%, foot surgery: 11.8 vs. 18.2%. Major complications: 50 vs. 56% (rocker bottom deformities: 23.5 vs. 46.3%, foot ulcerations: 17.6 vs. 24.6%, CF amputations: 0 vs. 6%), not CF amputations: 16.7 vs. 15.3%, second episodes of CF: 41.6 vs. 18.3% after 5–132months. Diabetic nephropathy was associated with an increase, intensive antihypertensive therapy with a decrease of complications.

Conclusions:

Patients with CF are middle-aged, overweight males with type 2 diabetes above 10 years. Patients with type 1 diabetes are younger, have normal BMI and longer diabetes duration. Major complications and second episodes of CF are frequent. Diabetic nephropathy could be a risk factor for CF related complications. The awareness for CF must be improved.

The study was conducted due to the Declaration of Helsinki.

Key words

charcot foot - neuropathic osteoarthropathy - diabetes mellitus

Volltext

Referenzen

References
1 Rajbhandari SM, Jenkins RC, Davies C et al. Charcot neuroarthropathy in diabetes mellitus. Diabetologia 2002; 45: 1085-1096
2 Sochocki MP, Verity S, Atherton PJ et al. Health related quality of life in patients with Charcot arthropathy of the foot and ankle. Foot Ankle Surg 2008; 14: 11-15
3 Sohn MW, Stuck RM, Pinzur M et al. Lower-extremity amputation risk after charcot arthropathy and diabetic foot ulcer. Diabetes Care 2010; 33: 98-100
4 Sohn MW, Lee TA, Stuck RM et al. Mortality risk of Charcot arthropathy compared with that of diabetic foot ulcer and diabetes alone. Diabetes Care 2009; 32: 816-821
5 Sanders LJ, Frykberg RG. Diabetic neuropathic osteoarthropathy: the Charcot foot. In: The high risk foot in diabetes mellitus. Frykberg RG. (Ed.). New York, NY: Churchill Livingstone; 1991: 297-338
6 Frykberg RG, Belczyk R. Epidemiology of the Charcot Foot. Clinics in Podiatric Medicine and Surgery. Clin Podiatr Med Surg 2008; 25: 17-28
7 Rogers LC, Bevilacqua NJ, Dellacorte MP et al. Charcot's arthropathy in a patient with HIV-associated neuropathy. J Am Podiatr Med Assoc 2008; 98: 153-155
8 Shibuya N, La Fontaine J, Frania SJ. Alcohol-induced neuroarthropathy in the foot: a case series and review of literature. J Foot Ankle Surg 2008; 47: 118-124
9 Rogers LC, Bevilacqua NJ. The diagnosis of Charcot foot. Clin Podiatr Med Surg 2008; Jan 25: 43-51
10 Trepman E, Nihal A, Pinzur MS. Current topics review: Charcot neuroarthropathy of the foot and ankle. Foot Ankle Int 2005; 26: 46-63
11 Wukich DK, Sung W. Charcot arthropathy of the foot and ankle: modern concepts and management review. J Diabetes Complications 2009; 23: 409-426
12 Frykberg RG, Mendeszoon E. Management of the Diabetic Charcot Foot. Diabetes Metabolism Research and Reviews 2000; 16 (Suppl. 01) S59-S65
13 Crews RT, Wrobel JS. Physical management of the Charcot foot. Clin Podiatr Med Surg 2008; 25: 71-79
14 Burns PR, Wukich DK. Surgical reconstruction of the Charcot rearfoot and ankle. Clin Podiatr Med Surg 2008; 25: 95-120
15 Armstrong DG, Todd WF, Lavery LA et al. The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. Diabet Med 1997; 14: 357-363
16 Fabrin J, Larsen K, Holstein PE. Long-term follow-up in diabetic Charcot feet with spontaneous onset. Diabetes Care 2000; 23: 796-800
17 Sanders LJ, Frykberg RG. Charcot Neuroarthropathy of the Foot. Evaluation: Techniques and Nonsurgical Management, Levin and O’Neal’s The Diabetic Foot. sixth edition, Mosby Inc.; 2001
18 Hilz MJ, Axelrod FB, Hermann K et al. Normative values of vibratory perception in 530 children, juveniles and adults aged 3–79 years. J Neurol Sci 1998; 159: 219-225
19 Miranda-Palma B, Sosenko JM, Bowker JH et al. A comparison of the monofilament with other testing modalities for foot ulcer susceptibility. Diabetes Res Clin Pract 2005; 70: 8-12
20 Chantelau E. The perils of procrastination: effects of early vs. delayed detection and treatment of incipient Charcot fracture. Diabet Med 2005; 22: 1707-1712
21 Edmonds ME, Petrova NL, Edmonds A et al. Early identification of bone marrow oedema in the Charcot foot on MRI allows rapid intervention to prevent deformity. Abstract. Diabetic Med 2006; 23 (Suppl. 02)
22 Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group . Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 15: 2563-2569
23 Sämann A, Tajiyeva O, Müller N et al. Prevalence of the diabetic foot syndrome at the primary care level in Germany: a cross-sectional study. Diabet Med 2008; 25: 557-563
24 Wolf G, Muller N, Busch M et al. Diabetic foot syndrome and renal function in type 1 and 2 diabetes mellitus show close association. Nephrol Dial Transplant 2009; 24: 1896-1901
25 Margolis DJ, Hofstad O, Feldman HI. Association between renal failure and foot ulcer or lower-extremity amputation in patients with diabetes. Diabetes Care 2008; 31: 1331-1336